March 17, 2014 4:42 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Below are the top small-cap drug manufacturers stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year.Lannett Company (NYSE: LCI) is likely to earn $2.08 per share in the next year ending June, 2015. Lannett's trailing-twelve-month operating margin is 13.06%.POZEN (NASDAQ: POZN) may earn $1.28 per share in the next year ending December, 2015. POZEN's PEG ratio is 0.43.DepoMed (NASDAQ: DEPO) is projected to earn $0.51 per share for the next year ending December, 2015. DepoMed's trailing-twelve-month revenue is $120.19 million.SciClone Pharmaceuticals (NASDAQ: SCLN) is expected to earn $0.45 per share over the next year ending December, 2015. SciClone Pharma's trailing-twelve-month ROE is 8.71%.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.